UBS Group
IDXX icon

UBS Group’s Idexx Laboratories IDXX Stock Holding History

UBS Group’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,100
Closed -$29.2M – 9768
2024
Q1 		$29.2M Buy
+54,100
New +$29.6M 0.01% 1407

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's IDXX Position: Q1 2026 in Review

UBS Group increased its Idexx Laboratories (IDXX) stake by 7.1% in Q1 2026, buying an estimated $13M and bringing the position to 305,167 shares worth $171M. The position accounts for 0.03% of the portfolio, ranked #694.

UBS Group first reported a position in IDXX in Q4 2014 and has held it in 46 quarters since. The position peaked at $224M in Q3 2025. 1,312 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • UBS Group held 305,167 shares of Idexx Laboratories worth $171M as of Q1 2026.
  • UBS Group bought 20,215 Idexx Laboratories shares in Q1 2026, an estimated $13M.
  • Idexx Laboratories made up 0.03% of UBS Group's portfolio in Q1 2026, its #694 holding.
  • UBS Group first reported a position in Idexx Laboratories in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Idexx Laboratories position peaked at $224M in Q3 2025.
  • 1,312 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.